From R&D to Compliance: Industry Trends and Quality Control of Protein Interaction and Signaling Pathway Detection Kits

Industry Drivers: Kit Innovation Under Precision Medicine and High-Throughput Demands

With the advancement of precision medicine and targeted therapies, protein interaction and signaling pathway detection kits are evolving from traditional single-target detection toward multi-parameter, high-throughput formats. In recent years, kits based on microfluidic chips and automated liquid-phase extraction technologies have gradually entered the market, enabling simultaneous assessment of more than ten protein-protein or protein-nucleic acid interaction events in a single experiment. Such products typically integrate pre-immobilized ligand-conjugated beads on 96-well or 384-well plates and distinguish different capture targets through encoded fluorescence or barcodes. From a regulatory perspective, some components may fall under the definition of in vitro diagnostic reagents. If intended for clinical samples, they must comply with the Provisions for the Registration and Administration of In Vitro Diagnostic Reagents and corresponding guidelines, requiring analytical performance studies (e.g., linear range, accuracy, precision) and stability data.

Core Quality Control Indicators: Sensitivity, Specificity, and Lot-to-Lot Stability

A high-quality kit must achieve nanomolar or even picomolar sensitivity while maintaining sufficient selectivity—cross-reactivity with homologous proteins or modified variants should typically be below 1%. For specificity, it is recommended to use knockout cell lysates or competitive peptides to verify the exclusivity of the target interaction. Lot-to-lot stability is the foundation for ensuring comparability within and between batches. Production processes generally require lyophilized powder aliquoting, addition of stabilizers (such as trehalose, mannitol), and incorporation of calcium ion chelators into buffers to control protease activity. Manufacturers need to establish internal quality controls (e.g., recombinant purified protein complexes) and conduct accelerated stability testing periodically to support the shelf life stated on the label.

Regulatory Compliance and Promotional Boundaries: Avoiding Efficacy Claims and Data Misrepresentation

When promoting protein interaction and signaling pathway detection kits in the Chinese market, the requirements of the Advertising Law regarding advertisements for medical devices and in vitro diagnostic reagents must be strictly observed. Product promotion must not use absolute statements such as "100% diagnostic rate" or "completely interference-free." When describing sensitivity, it should state "the minimum detectable concentration under specific conditions is XX pM" rather than "can detect any trace sample." For research-use kits, "For Research Use Only (RUO)" must be clearly labeled, and no implication of clinical diagnostic capability is permitted. Formal copy should also avoid directly citing unpublished third-party data. If published literature is cited, a reference list must be attached and the selected parameters explained.

Expanding Application Areas: From Basic Research to Drug Screening and Clinical Translation

Beyond traditional laboratory applications, protein interaction and signaling pathway detection kits are increasingly integrated into antibody drug screening, binding kinetics evaluation, and patient stratification studies. For example, candidate antibody affinity activity can be assessed by measuring the inhibition rate of PD-1/PD-L1 interaction, or abnormalities in protein degradation pathways can be indirectly reflected using ubiquitin ligase-substrate interaction kits. In translational medicine, some clinically validated kits can be used to monitor early patient responses to signaling pathway-targeted therapies (such as MEK inhibitors). However, such applications must be approved by ethics committees and performed within the scope of registration certificates. For products about to be regulatory-upgraded to Class III medical devices, manufacturers need to prepare clinical evaluation materials in advance, including results from multicenter retrospective or prospective studies.

Considerations for Self-Development: System Optimization and Experimental Reproducibility

If a laboratory wishes to prepare its own detection system similar to commercial kits, it must focus on controlling key parameters such as buffer formulation (ionic strength, pH, detergent type), incubation temperature and time, and wash cycles. It is recommended to prioritize the use of internal quality controls for generating standard curves and to include maximum and minimum signal groups in each experimental run. Additionally, antibody stability should be regularly verified to avoid repeated freeze-thaw cycles. When publishing data or participating in third-party evaluations, report reagent sources, lot numbers, working concentrations, and experimental batches in accordance with journal guidelines such as those of Experimental Biology and Medicine to ensure reproducibility of results.